Additionally, the 36-month beta value for MESO is 2.41. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for MESO is 127.00M and currently, short sellers hold a 2.12% ratio of that float. The average trading volume of MESO on July 02, 2025 was 208.73K shares.
MESO) stock’s latest price update
Mesoblast Ltd ADR (NASDAQ: MESO)’s stock price has increased by 11.29 compared to its previous closing price of 10.89. However, the company has seen a 15.98% increase in its stock price over the last five trading sessions. benzinga.com reported 2025-07-01 that On Monday, Mesoblast Ltd. MESO announced alignment with the U.S. Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor (rexlemestrocel-L) for ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation.
MESO’s Market Performance
Mesoblast Ltd ADR (MESO) has experienced a 15.98% rise in stock performance for the past week, with a 13.91% rise in the past month, and a -2.88% drop in the past quarter. The volatility ratio for the week is 3.44%, and the volatility levels for the past 30 days are at 3.70% for MESO. The simple moving average for the past 20 days is 6.40% for MESO’s stock, with a -1.93% simple moving average for the past 200 days.
Analysts’ Opinion of MESO
Maxim Group, on the other hand, stated in their research note that they expect to see MESO reach a price target of $12. The rating they have provided for MESO stocks is “Buy” according to the report published on September 24th, 2024.
MESO Trading at 7.03% from the 50-Day Moving Average
After a stumble in the market that brought MESO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.91% of loss for the given period.
Stock Fundamentals for MESO
Current profitability levels for the company are sitting at:
- -15.04 for the present operating margin
- -3.98 for the gross margin
The net margin for Mesoblast Ltd ADR stands at -18.23. The total capital return value is set at -0.15. Equity return is now at value -21.26, with -15.58 for asset returns.
Based on Mesoblast Ltd ADR (MESO), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -0.16.
Currently, EBITDA for the company is -56.08 million with net debt to EBITDA at -1.78. When we switch over and look at the enterprise to sales, we see a ratio of 263.85. The receivables turnover for the company is 3.36for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.96.
Conclusion
In conclusion, Mesoblast Ltd ADR (MESO) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
